It is the most searched peptide in America and it has no published randomised controlled trial in humans for any indication. Both of those things are true at the same time, and the gap between them is the whole story.
The short version. BPC-157 is not FDA approved. In July 2026 an advisory committee recommended it for the list that governs what compounding pharmacies may legally prepare, by a vote of 8 to 6 with one abstention. That recommendation is not a rule and does not make anything legal by itself. There is no published randomised controlled trial of it in humans, and therefore no approved dose for anyone to follow.
BPC-157 is a synthetic peptide of 15 amino acids, sequence GEPPPGKPADDAGLV. It is usually described as a fragment of a protein found in human gastric juice, which is where the name comes from: body protection compound.
That description is accurate and it is also doing a lot of marketing work. A molecule being derived from something the body already makes tells you nothing about whether a manufactured version of it, at an unknown dose, by an unapproved route, does what anyone claims. Insulin is also something the body makes.
The sequence of events matters more than any single one of them, so here it is in order, with dates.
| When | What happened | What it means |
|---|---|---|
| 2023 | FDA places BPC-157 in Category 2 of the 503A bulks list | Category 2 signals a significant safety concern. In this case immunogenicity and impurities. |
| 15 April 2026 | FDA removes BPC-157 from Category 2 | The safety flag comes off. This is not an approval. |
| 23 and 24 July 2026 | Pharmacy Compounding Advisory Committee votes 8-6-1 in favour of adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List | A recommendation to the agency. One vote short of a third of the committee voted against. |
| Still pending | Notice-and-comment rulemaking | Typically 8 to 12 months. Until it concludes, no compounding pharmacy has unambiguous authority to prepare it. |
The distance between a committee recommendation and a rule is where most of the confusion on this subject lives, and a lot of it is being manufactured. A vote of 8 to 6 with an abstention is a narrow, contested recommendation, not a finding that a compound is safe and effective. It says a majority of a committee thought it was suitable for pharmacy compounding. It does not say it works.
A 2025 systematic review included 36 studies. Of those, 35 were preclinical and one was clinical.
There is no published, peer-reviewed randomised controlled trial of BPC-157 in humans for any indication. The entire human literature consists of three uncontrolled pilot studies totalling fewer than 30 subjects between them, and none of them used a standardised pharmaceutical preparation. That last detail is easy to skim past and it is important: without a standardised preparation, the studies cannot even be compared to each other, let alone to whatever a given vial contains.
The preclinical work, almost all of it in animals, is where every claim you have read originates. It examines healing in tendon, ligament, muscle and bone injury, and reports effects on growth hormone receptor expression, on pathways involved in cell growth and angiogenesis, and on inflammatory cytokines. Those are real published findings. They are findings in animals. The step from there to a human outcome is the step nobody has taken in a controlled trial.
In 2025, Lee and Burgess ran a pilot in which two healthy adults received intravenous infusions of up to 20 mg. It was well tolerated: no adverse events, and no clinically meaningful changes in vital signs, electrocardiograms or other biomarkers.
That is a genuine result and it is worth reporting accurately in both directions. It is the best human safety signal that exists. It is also two people. A separate 2025 systematic review found no clinical safety data at all. Neither of those statements cancels the other out, and a page that gives you only one of them is selling something.
There is no approved dose of BPC-157, because there is no approval and therefore no label.
This is not a technicality and it is not us being careful. It is the single most important fact about every dosing figure you will find for this compound. An approved dose exists because a regulator reviewed trial data and wrote a number on a label. For BPC-157 that process has not happened, so any number in circulation came from somewhere else: a forum, a vendor, a clinic protocol, or someone reading an animal study and converting by bodyweight.
The only figure in the peer-reviewed human literature is the one above: intravenous, up to 20 mg, in two people, in a pilot designed to look at tolerability rather than effect. It is not a recommendation, it was not compared against anything, and it was not the route most people are being sold.
We report that number because it is the record. We do not publish a recommended dose, a protocol or a schedule, for this or any compound, and we would not be able to source one if we tried.
One test settles most of it. Look at who is publishing, and look at whether the page distinguishes between a committee recommendation and a rule. Nearly every site ranking for this compound sells it, prescribes it, or sells a consultation that leads to it, and nearly every one of them describes July 2026 as though the question were closed.
It is not closed. That is the accurate position as of 24 September 2026, and this page carries a date at the top so you can tell when it stops being current.
No. BPC-157 is not approved by the FDA for any use in humans as of September 2026. A July 2026 advisory committee vote recommending it for the 503A compounding list is a recommendation about compounding, not an approval of the drug.
No. The Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend adding BPC-157 to the 503A Bulks List. A committee recommendation is advisory. The FDA must still complete formal notice-and-comment rulemaking, which typically takes 8 to 12 months, before compounding pharmacies have unambiguous authority to prepare it.
Its position is unsettled rather than settled either way. It was removed from Category 2 of the 503A bulks list on 15 April 2026 and recommended for the list in July 2026, but the rulemaking that would place it there has not happened. Material sold online as "research use only" is not a prescription medicine and is not prepared by a licensed compounding pharmacy.
There is no published, peer-reviewed randomised controlled trial of BPC-157 in humans for any indication. A 2025 systematic review included 36 studies, of which 35 were preclinical and one was clinical. The human literature consists of three uncontrolled pilot studies totalling fewer than 30 subjects, none of which used a standardised pharmaceutical preparation.
There is no approved dose, because there is no approval and therefore no label. The only documented human exposure in the peer-reviewed literature is a 2025 pilot by Lee and Burgess in which two healthy adults received intravenous infusions of up to 20 mg. Any other figure in circulation does not come from a label or from a controlled trial.
The honest answer is that it has not been studied enough in humans to say. One major 2025 systematic review found no clinical safety data at all. In the 2025 two-person pilot, intravenous infusions of up to 20 mg were well tolerated, with no adverse events and no clinically meaningful changes in vital signs, electrocardiograms or other biomarkers. Two subjects is not a safety database. The FDA's own 2023 concerns were immunogenicity and impurities.
Nothing, officially. It has no approved indication. The preclinical literature, almost all of it in animals, examines healing in tendon, ligament, muscle and bone injury, along with effects on growth hormone receptor expression, angiogenesis pathways and inflammatory cytokines. Those are findings in animals, not established uses in people.
They are two salt forms of the same peptide. The July 2026 advisory committee vote covered both, which matters because compounding rules are written against specific substances rather than against a compound in the abstract.
There is no licensed route to this compound, because it has no approval. What does exist is a clinician who can look at why you were considering it in the first place. These platforms connect to clinicians licensed in your state.
Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.
Ozemback is not a provider and takes no part in any clinical decision. Some of these links are affiliate links: if you start a consultation or buy a panel through one, we may receive a commission at no additional cost to you. We are paid for the referral, never for the outcome, and it does not change what we publish.